Literature DB >> 34116813

Utilizing patient perception of group treatment in exploring medication adherence, social support, and quality of life outcomes in people who inject drugs with hepatitis C.

Kerry A Howard1, Lior Rennert1, Irene Pericot-Valverde2, Moonseong Heo1, Brianna L Norton3, Matthew J Akiyama3, Linda Agyemang3, Alain H Litwin4.   

Abstract

People who inject drugs (PWID) have a high prevalence of hepatitis C virus (HCV). Group treatment is a practical option for addressing barriers to treatment in this population. Prior research on group treatment has resulted in mixed conclusions about its effectiveness in addressing barriers to treatment. A patient's perception of the group environment may help to explain this variability. This study sought to explore the association between indicators of group treatment environment and improved outcomes in HCV-infected PWID. This secondary analysis of a randomized controlled trial exploring different models of treatment for HCV in a PWID population consisted of 42 participants randomized to the group treatment branch of the trial. Independent variables consisted of group sessions attended and group climate constructs of engagement, conflict, and avoidance. Dependent variables consisted of medication adherence, social support, and health-related quality of life. The study implemented generalized estimating equations to assess associations with the outcomes at the end of treatment. Factors indicative of group treatment environment were related to medication adherence and other barriers to health for HCV-infected PWID: social support and health-related quality of life. Perceptions of conflict or avoidance were associated with worse outcomes, while increased session attendance was generally associated with better outcomes. The study attests to the importance of examining group environment factors during treatment interventions. Although preliminary, the study provides specific indicators of treatment success for HCV-infected PWID and practical implications to improve patients' health outcomes and better tailor treatment to the patient.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Group climate; Group treatment; Hepatitis C virus; People who inject drugs

Mesh:

Substances:

Year:  2021        PMID: 34116813      PMCID: PMC8714173          DOI: 10.1016/j.jsat.2021.108459

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  42 in total

1.  Process and treatment adherence factors in group cognitive-behavioral therapy for partner violent men.

Authors:  Casey T Taft; Christopher M Murphy; Daniel W King; Peter H Musser; Judith M DeDeyn
Journal:  J Consult Clin Psychol       Date:  2003-08

Review 2.  The concordance of self-report with other measures of medication adherence: a summary of the literature.

Authors:  Mathew C Garber; David P Nau; Steven R Erickson; James E Aikens; Joseph B Lawrence
Journal:  Med Care       Date:  2004-07       Impact factor: 2.983

Review 3.  Group therapy for substance use disorders: what do we know?

Authors:  Roger D Weiss; William B Jaffee; Victoria P de Menil; Catherine B Cogley
Journal:  Harv Rev Psychiatry       Date:  2004 Nov-Dec       Impact factor: 3.732

4.  Inference in regression models of heavily skewed alcohol use data: a comparison of ordinary least squares, generalized linear models, and bootstrap resampling.

Authors:  Dan J Neal; Jeffrey S Simons
Journal:  Psychol Addict Behav       Date:  2007-12

5.  Social difficulties influence group psychotherapy adherence in abused, suicidal African American women.

Authors:  Dawn L Ilardi; Nadine J Kaslow
Journal:  J Clin Psychol       Date:  2009-12

6.  Group dynamics are associated with weight loss in the behavioral treatment of obesity.

Authors:  Lisa M Nackers; Pamela J Dubyak; Xiaomin Lu; Stephen D Anton; Gareth R Dutton; Michael G Perri
Journal:  Obesity (Silver Spring)       Date:  2015-07-14       Impact factor: 5.002

7.  Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.

Authors:  J E Ware; M S Bayliss; M Mannocchia; G L Davis
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

8.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

9.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.

Authors:  Jeffrey D Stanaway; Abraham D Flaxman; Mohsen Naghavi; Christina Fitzmaurice; Theo Vos; Ibrahim Abubakar; Laith J Abu-Raddad; Reza Assadi; Neeraj Bhala; Benjamin Cowie; Mohammad H Forouzanfour; Justina Groeger; Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Spencer L James; Jennifer MacLachlan; Reza Malekzadeh; Natasha K Martin; Ali A Mokdad; Ali H Mokdad; Christopher J L Murray; Dietrich Plass; Saleem Rana; David B Rein; Jan Hendrik Richardus; Juan Sanabria; Mete Saylan; Saeid Shahraz; Samuel So; Vasiliy V Vlassov; Elisabete Weiderpass; Steven T Wiersma; Mustafa Younis; Chuanhua Yu; Maysaa El Sayed Zaki; Graham S Cooke
Journal:  Lancet       Date:  2016-07-07       Impact factor: 79.321

10.  Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.

Authors:  Omar Elsherif; Ciaran Bannan; Shay Keating; Susan McKiernan; Colm Bergin; Suzanne Norris
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.